重组人红细胞生成素治疗肾性贫血的效果观察

Clinical outcomes of recombinant human erythropoietin in treatment of renal anemia

目的观察重组人红细胞生成素(rhEPO)治疗慢性肾功能衰竭患者肾性贫血的效果。方法予20例慢性肾功能衰竭合并肾性贫血患者应用国产rhEPO皮下注射治疗12～24周。结果用药前后自身对比显示:血红蛋白、红细胞压积、网织红细胞从给药第2周起显著升高(P<0.05或0.01);白细胞、血小板、肝功能、肾功能、血清离子无明显改变(P均>0.05)。疗效判定:显效率55%,有效率30%,无效率15%。结论rhEPO治疗肾性贫血安全可靠、疗效确切。

Objective To evaluate the clinical efficacy of recombinant human erythropoietin （rhEPO） in treatment of patients with renal anemia due to chronic kidney failure. Methods 20 patients with chronic kidney failure associated with renal anemia were involved in this study. The patients were given subcutaneous rhEPO for 12- 24 weeks. Results Compared to before treatment ： the elevated levels of hemoglobin, packed cell volume, and reticulated corpuscles were found from week 2, there were statistically significant differences （ P 〈0.05 or 0.01）. While the levels of white blood cells, platelet, kidney function and serum ion were almost the same, compared to before treatment, there were no statistically significant differences （ P 〉0.05）. The excellent curative rate was 55%, the good curative rate was 30%, and the ineffective rate was 15%. Conclusion rhEPO in treatment of renal anemia is safe and effective.